問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Link to Hospital

  • 2,634

    Total Beds

  • 1,095

    Total Doctors

  • jmventcc@cgmh.org.tw
  • CHANG-CHIEN, CHIA-MIN
  • 07-7317123#6416
  • 833Kaohsiung CityKaohsiung NiaosongNo. 123, Dapi Rd., Niaosong Dist., Kaohsiung City 833 , Taiwan (R.O.C.)

Recruiting Trial

588Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1457Cases

2010-04-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Study ended7Sites

2007-11-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-11-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2008-08-15 - 2010-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-11-01 - 2030-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-12-01 - 2021-06-29

Phase II/III

A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Condition/Disease

    Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    GSK3359609

Participate Sites
7Sites

Recruiting1Sites

Terminated6Sites

2021-10-01 - 2024-03-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-12-07 - 2025-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2022-12-01 - 2027-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2024-01-01 - 2026-12-31

Phase III

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

  • Condition/Disease

    moderate-to-severe plaque psoriasis

  • Test Drug

    TAK-279Apremilast

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

1 98 99 100 101 102 146
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB